HWAM
AMRX icon

Hennion & Walsh Asset Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-52,339
Closed -$73K – 800
2023
Q1 		$73K Sell
52,339
-1,731
-3% -$3.45K ﹤0.01% 765
2022
Q4 		$108K Sell
54,070
-7,870
-13% -$17.6K 0.01% 755
2022
Q3 		$125K Sell
61,940
-3,184
-5% -$8.92K 0.01% 749
2022
Q2 		$207K Sell
65,124
-925
-1% -$3.35K 0.01% 719
2022
Q1 		$275K Sell
66,049
-4,464
-6% -$19.8K 0.01% 677
2021
Q4 		$338K Buy
70,513
+1,598
+2% +$7.97K 0.02% 622
2021
Q3 		$368K Buy
68,915
+20,745
+43% +$104K 0.02% 587
2021
Q2 		$247K Buy
+48,170
New +$274K 0.01% 668

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Hennion & Walsh Asset Management's AMRX Position: Q2 2023 in Review

Hennion & Walsh Asset Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2023, closing a stake of 52,339 shares — an estimated $73K sold.

Hennion & Walsh Asset Management first reported a position in AMRX in Q2 2021 and held it in 8 quarters. The position peaked at $368K in Q3 2021. 128 funds tracked by Wall St. Rank hold AMRX as of Q2 2023.

  • Hennion & Walsh Asset Management reported no remaining Amneal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Hennion & Walsh Asset Management sold 52,339 Amneal Pharmaceuticals shares in Q2 2023, an estimated $73K.
  • Hennion & Walsh Asset Management first reported a position in Amneal Pharmaceuticals in Q2 2021 and held it in 8 quarters.
  • Hennion & Walsh Asset Management's Amneal Pharmaceuticals position peaked at $368K in Q3 2021.
  • 128 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2023.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2023, filed 9 Aug 2023.